Metin Unlu1, Zeynep Aktas2, Pinar Uyar Gocun3, Sevil Ozger Ilhan4, Murat Hasanreisoglu2, Berati Hasanreisoglu2. 1. Department of Ophthalmology, Erciyes University, School of Medicine, Kayseri 38039, Turkey. 2. Department of Ophthalmology, Gazi University, School of Medicine, Besevler, Ankara 06560, Turkey. 3. Department of Pathology, Gazi University, School of Medicine, Besevler, Ankara 06560, Turkey. 4. Department of Pharmacology, Gazi University, School of Medicine, Besevler, Ankara 06560, Turkey.
Abstract
AIM: To evaluate the neuroprotective effect of rosuvastatin, in a rat experimental glaucoma model. METHODS: Ocular hypertension was induced in right eyes of Long-Evans rats (n=30) by cauterization of three episcleral veins. Left eyes were defined as controls. Rats were divided into five groups: oral rosuvastatin, intravitreal rosuvastatin, oral+intravitreal rosuvastatin, intravitreal sham and glaucoma without intervention. Rats were sacrificed at day 14. Retinal ganglion cell (RGC) number was assessed by histopathological analysis. Terminal deoxynucleotidyl transferase-mediated dUTP-nick end-labeling (TUNEL) staining and the expression of glial fibrillary acidic protein (GFAP) in RGC layer was also examined. RESULTS: A significant intraocular pressure (IOP) elevation was seen (P=0.002). Elevated IOP resulted in a significant decrease in number of RGCs in group 5 (70.33±8.2 cells/mm(2)) when compared with controls (92.50±13.72 cells/mm(2); P=0.03). The RGC number in group 1 (92.4±7.3 cells/mm(2)) was significantly higher than group 5 (P=0.03). The numbers of RGC in groups 2, 3 (57.3±8.2 cells/mm(2), 60.5±12.9 cells/mm(2)) were comparable with that of group 5 (P=0.18 and P=0.31). The apoptosis rates with TUNEL staining were also parallel to RGC number. Animals with experimentally induced glaucoma showed an increase in retinal GFAP immunoreactivity. CONCLUSION: Decrease in RGC loss and apoptosis suggest the neuroprotective potential of oral rosuvastatin treatment in a rat model of ocular hypertension. However intravitreal rosuvastatin showed a contrary effect and further studies are required.
AIM: To evaluate the neuroprotective effect of rosuvastatin, in a rat experimental glaucoma model. METHODS:Ocular hypertension was induced in right eyes of Long-Evansrats (n=30) by cauterization of three episcleral veins. Left eyes were defined as controls. Rats were divided into five groups: oral rosuvastatin, intravitreal rosuvastatin, oral+intravitreal rosuvastatin, intravitreal sham and glaucoma without intervention. Rats were sacrificed at day 14. Retinal ganglion cell (RGC) number was assessed by histopathological analysis. Terminal deoxynucleotidyl transferase-mediated dUTP-nick end-labeling (TUNEL) staining and the expression of glial fibrillary acidic protein (GFAP) in RGC layer was also examined. RESULTS: A significant intraocular pressure (IOP) elevation was seen (P=0.002). Elevated IOP resulted in a significant decrease in number of RGCs in group 5 (70.33±8.2 cells/mm(2)) when compared with controls (92.50±13.72 cells/mm(2); P=0.03). The RGC number in group 1 (92.4±7.3 cells/mm(2)) was significantly higher than group 5 (P=0.03). The numbers of RGC in groups 2, 3 (57.3±8.2 cells/mm(2), 60.5±12.9 cells/mm(2)) were comparable with that of group 5 (P=0.18 and P=0.31). The apoptosis rates with TUNEL staining were also parallel to RGC number. Animals with experimentally induced glaucoma showed an increase in retinal GFAP immunoreactivity. CONCLUSION: Decrease in RGC loss and apoptosis suggest the neuroprotective potential of oral rosuvastatin treatment in a rat model of ocular hypertension. However intravitreal rosuvastatin showed a contrary effect and further studies are required.
Entities:
Keywords:
neuroprotection; rat glaucoma model; retinal ganglion cell number; rosuvastatin
Authors: Joshua D Stein; Paula Anne Newman-Casey; Nidhi Talwar; Bin Nan; Julia E Richards; David C Musch Journal: Ophthalmology Date: 2012-06-21 Impact factor: 12.079
Authors: T W Mittag; J Danias; G Pohorenec; H M Yuan; E Burakgazi; R Chalmers-Redman; S M Podos; W G Tatton Journal: Invest Ophthalmol Vis Sci Date: 2000-10 Impact factor: 4.799
Authors: F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald Journal: N Engl J Med Date: 1996-10-03 Impact factor: 91.245
Authors: M Iskedjian; J H Walker; O Desjardins; A L Robin; D W Covert; M V W Bergamini; T R Einarson Journal: Curr Med Res Opin Date: 2009-08 Impact factor: 2.580
Authors: David Garcia-Herranz; Maria Jesus Rodrigo; Manuel Subias; Teresa Martinez-Rincon; Silvia Mendez-Martinez; Irene Bravo-Osuna; Aina Bonet; Jesus Ruberte; Julian Garcia-Feijoo; Luis Pablo; Elena Garcia-Martin; Rocío Herrero-Vanrell Journal: Pharmaceutics Date: 2021-02-08 Impact factor: 6.321